{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:00:32Z","timestamp":1790290832333,"version":"4.1.0"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High-grade prostate cancer (International Society of Urological Pathology [ISUP] grade groups 4 and 5) is often aggressive and associated with early metastatic spread. Gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) is widely adopted for prostate cancer imaging due to its high sensitivity, while F-18 fluorodeoxyglucose (FDG) PET\/CT may provide complementary metabolic information. This study investigates and compares the diagnostic performance of these two modalities and evaluates the incremental value of dual-tracer PET\/CT imaging.<\/jats:p>\n                  <jats:p>This prospective observational study included 51 patients with biopsy-proven, high-grade prostate adenocarcinoma (ISUP grade groups 4 and 5) undergoing both Ga-68 PSMA and F-18 FDG PET\/CT within 1 week. Detection rates for primary tumors, nodal, and distant metastases were analyzed. Maximum standardized uptake values (SUVmax), lesion-to-aorta and lesion-to-muscle ratios, and serum prostate-specific antigen (PSA) levels were correlated.<\/jats:p>\n                  <jats:p>Ga-68 PSMA PET\/CT demonstrated superior detection rate for primary tumor detection (90.2%) compared to F-18 FDG PET\/CT (66.7%, p\u2009=\u20090.004). For pelvic lymph nodes, detection rates were numerically higher with PSMA PET\/CT (76.2% vs. 59.5% for FDG PET\/CT), although this difference did not reach statistical significance; for extrapelvic lymph nodes, 95.2% (PSMA) versus 52.4% (FDG, p\u2009=\u20090.02); and for bone lesions, 100% (PSMA) versus 77.8% (FDG, p\u2009=\u20090.009). In ISUP grade 4, primary detection was 94.4% (PSMA) versus 50% (FDG, p\u2009=\u20090.003); in grade 5, 87.9% (PSMA) versus 75.8% (FDG). Dual-tracer imaging improved overall detection of primary tumors and pelvic lymph nodes to 100 and 90.4%, respectively. A mild correlation was observed between PSA levels and PSMA SUVmax (r\u2009=\u20090.297, p\u2009=\u20090.034). Strong positive correlations were found between SUVmax and both lesion-to-aorta and lesion-to-muscle ratios for both tracers. Interreader agreement was excellent for PSMA (\u03ba\u2009=\u20091.00) and high for FDG (\u03ba\u2009=\u20090.95).<\/jats:p>\n                  <jats:p>Ga-68 PSMA PET\/CT demonstrated high detection rates for detecting primary and metastatic lesions in high-grade prostate cancer. F-18 FDG PET\/CT offers complementary metabolic information, particularly valuable in ISUP grade 5 and dedifferentiated tumors. Dual-tracer PET\/CT enhances diagnostic accuracy and may facilitate personalized treatment strategies in aggressive prostate cancer.<\/jats:p>","DOI":"10.1055\/s-0046-1825755","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:12:11Z","timestamp":1784157131000},"page":"232-241","source":"Crossref","is-referenced-by-count":0,"title":["Prospective Intraindividual Comparison of Ga-68 PSMA and F-18 FDG Dual-Tracer PET\/CT Imaging in Evaluation of High-Grade Prostate Cancer"],"prefix":"10.1055","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3715-2170","authenticated-orcid":false,"given":"Harini","family":"Koorma","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET-CT, Asian Institute of Gastroenterology (AIG) Hospitals, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan Roop","family":"Jayanthi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET-CT, Asian Institute of Gastroenterology (AIG) Hospitals, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneetha","family":"Batchu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET-CT, Asian Institute of Gastroenterology (AIG) Hospitals, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Sekaran","sequence":"additional","affiliation":[{"name":"Department of Pathology, Asian Institute of Gastroenterology (AIG) Hospitals, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Kumar","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Urology, Asian Institute of Nephrology and Urology (AINU), Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallikarjuna","family":"Chiruvella","sequence":"additional","affiliation":[{"name":"Department of Urology, Asian Institute of Nephrology and Urology (AINU), Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"P Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"N D James","year":"2024","journal-title":"Lancet"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/jm0306226","article-title":"Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents","volume":"47","author":"A P Kozikowski","year":"2004","journal-title":"J Med Chem"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1091\/mbc.e02-11-0731","article-title":"A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen","volume":"14","author":"S A Rajasekaran","year":"2003","journal-title":"Mol Biol Cell"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JU.0000000000000531","article-title":"Prospective validation of gallium-68 prostate specific membrane antigen-positron emission tomography\/computerized tomography for primary staging of prostate cancer","volume":"203","author":"L WM van Kalmthout","year":"2020","journal-title":"J Urol"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3413\/Nukmed-0668-14-05","article-title":"Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland. Systematic review and meta-analysis on prevalence and risk of malignancy","volume":"53","author":"F Bertagna","year":"2014","journal-title":"Nuklearmedizin"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","article-title":"Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging","volume":"37","author":"E Demirci","year":"2016","journal-title":"Nucl Med Commun"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"M S Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/0284186X.2010.542174","article-title":"Tumor markers in prostate cancer I: blood-based markers","volume":"50","author":"S F Shariat","year":"2011","journal-title":"Acta Oncol"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.18231\/j.ijpo.2020.043","article-title":"Correlation between Gleason score of adenocarcinoma prostate and serum PSA levels in the western Himalayan region of India","volume":"7","author":"N Sharma","year":"2020","journal-title":"Ind J Pathol Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"585213","DOI":"10.3389\/fonc.2020.585213","article-title":"Intra-individual comparison of 18F-PSMA-1007 and 18F-FDG PET\/CT in the evaluation of patients with prostate cancer","volume":"10","author":"X Zhou","year":"2021","journal-title":"Front Oncol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12149-010-0424-4","article-title":"The potential of FDG-PET\/CT for detecting prostate cancer in patients with an elevated serum PSA level","volume":"25","author":"R Minamimoto","year":"2011","journal-title":"Ann Nucl Med"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.euf.2018.03.008","article-title":"Increased prostate cancer glucose metabolism detected by 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in localised Gleason 8\u201310 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration","volume":"5","author":"E Lavall\u00e9e","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"S 03","key":"ref14","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.2967\/jnumed.115.170704","article-title":"PET of glucose metabolism and cellular proliferation in prostate cancer","volume":"57","author":"H Jadvar","year":"2016","journal-title":"J Nucl Med"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/1097-0142(20001101)89:9<2018::AID-CNCR19>3.0.CO;2-Y","article-title":"Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study","volume":"89","author":"B Movsas","year":"2000","journal-title":"Cancer"},{"issue":"06","key":"ref16","first-page":"1561","article-title":"Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score","volume":"20","author":"G D Stewart","year":"2008","journal-title":"Oncol Rep"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/diagnostics14010007","article-title":"18F-FDG PET is not inferior to 68Ga-PSMA PET for detecting biochemical recurrent prostate cancer with a high Gleason score: a head-to-head comparison study","volume":"14","author":"L Xu","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/MNM.0000000000001371","article-title":"Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system (\u2018Pro-PET\u2019 score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis","volume":"42","author":"A Adnan","year":"2021","journal-title":"Nucl Med Commun"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0090-4295(00)00896-7","article-title":"Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer","volume":"57","author":"I J Liu","year":"2001","journal-title":"Urology"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.262250","article-title":"The added value of 18F-FDG PET\/CT compared with 68Ga-PSMA PET\/CT in patients with castration-resistant prostate cancer","volume":"63","author":"R Chen","year":"2022","journal-title":"J Nucl Med"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41391-020-0202-x","article-title":"GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET\/CT and clinical outcome","volume":"23","author":"S Meziou","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0046-1825755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:30:49Z","timestamp":1790289049000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0046-1825755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":21,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,9,24]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0046-1825755","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}